2024-11-24 - Analysis Report
## Johnson & Johnson (JNJ) Stock Report

This report analyzes Johnson & Johnson (JNJ), a multinational healthcare corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.


**1. Performance vs. S&P 500 (VOO):**

JNJ's cumulative return of 36.03% significantly underperformed the S&P 500's 127.58% over the analyzed period. The  difference is -91.55%, placing it at the 2.45th percentile of its historical range (max: 17.07%, min: -94.28%).  This indicates substantial underperformance relative to the broader market.  The provided CAGR data (Compound Annual Growth Rate) shows JNJ's performance fluctuating year-over-year, sometimes exceeding the market and sometimes falling considerably short.  The Beta consistently below 1 indicates lower volatility than the overall market. Alpha fluctuates across years, sometimes exceeding the market and sometimes underperforming it.

**2. Recent Price Movement:**

* **Closing Price:** $155.15
* **5-Day Moving Average:** $154.31
* **20-Day Moving Average:** $156.36
* **60-Day Moving Average:** $161.14

The price is currently below its 20-day and 60-day moving averages, suggesting a potential downward trend.  The proximity to the 5-day moving average suggests recent price consolidation.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 39.91 - This indicates the stock is in oversold territory, suggesting a potential bounce.
* **PPO (Percentage Price Oscillator):** 0.05 -  A near-zero PPO suggests a lack of strong momentum, either bullish or bearish.
* **20-Day Relative Divergence:** -3.73 -  The negative value indicates a recent short-term downward trend in relative performance.
* **Expected Return:** 0.0% - This suggests that, based on the provided data, no significant outperformance relative to the S&P 500 is expected in the long term (2+ years) using a buy-and-hold strategy.

**4. Recent Financial Performance and Outlook:**

The provided EPS (Earnings Per Share) and revenue data show some fluctuation.  While revenue remains relatively consistent, EPS varies significantly.  There is no comparison with earnings estimates provided.  To provide a complete picture, a comparison of actual results with analyst forecasts is necessary for a more thorough evaluation.

**5. Financial Information:**

* **Revenue and Profitability:** Shows strong and relatively consistent revenue with high profit margins across the reported quarters.
* **Capital and Profitability:** ROE (Return on Equity) fluctuates but is generally positive, indicating profitability. The extremely high ROE in 2023-Q3 is notable and requires further investigation to understand the underlying cause.

**6. News and Recent Issues:**

* *(Information missing.  To complete this section, please provide recent news articles, press releases, or analyst reports on JNJ within the last 2 days.  Sources like Seeking Alpha, Yahoo Finance, and company press releases would be helpful.)*


**7. Recent Market Outlook, Analyst Opinions, and Performance Highlights:**

*(Information missing.  To complete this section, please provide relevant market outlook information, analyst ratings, and summaries of recent performance highlights for JNJ.  Financial news websites like Finbold and others can help supplement this data.)*


**8. Overall Analysis:**

JNJ has consistently shown strong revenue and profitability. However, its stock performance has lagged significantly behind the S&P 500 over the period analyzed.  While technical indicators suggest potential for a short-term bounce (oversold RSI), the long-term outlook, based on the provided expected return, is not particularly optimistic compared to the broader market.  Crucially, a thorough analysis of the Q3 2023 exceptionally high ROE and a comparison of actual earnings with analyst expectations are vital for a complete assessment.  More current news and analyst opinions would provide further context for investment decisions.


**9. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing involves risk, and past performance is not indicative of future results.  Consult with a qualified financial advisor before making any investment decisions.
